42 results on '"Langer, C.J."'
Search Results
2. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
3. MA14.04 Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC
4. P2.02-02 Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer
5. 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
6. P3.06D.06 Incremental Value of Liquid Biopsy in the Initial Evaluation of Non-Small Cell Lung Cancer Patients Undergoing Tissue Based Molecular Testing
7. OA06.04 Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
8. 1068P Predicting response to pembrolizumab in non-small cell lung cancer using spatial analysis of biopsy images by deep learning
9. P1.15-07 Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
10. 889MO Comparative expression of driver transcription factors in extra-pulmonary small cell carcinoma
11. OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors
12. EP08.01-076 KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
13. 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
14. 1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
15. FP06.02 Treatment Decision-Making and Decisional Support Experiences Among Lung Cancer Patients and Survivors
16. OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
17. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial
18. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
19. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
20. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
21. Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
22. Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial
23. Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
24. High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data
25. Brigatinib in crizotinib-refractory ALK+ NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
26. LBA80 - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
27. 1543P - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial
28. 1483PD - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
29. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
30. 1363O - Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
31. 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
32. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study
33. Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses
34. Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
35. LBA49 - Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
36. 1367P - Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial
37. 1344P - Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
38. 1064P - High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data
39. 97P - Brigatinib in crizotinib-refractory ALK+ NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
40. LBA4 - Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
41. 99O - Phase 1/2 Study of Ap26113 in Patients (PTS) with Advanced Malignancies, Including Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC): Analysis of Safety and Efficacy at Selected Phase 2 Doses
42. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.